Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked faithfully but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last several shares. The 1st CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire job interview that I came away with a poor opinion of the company.

Irony of irony, the bad opinion of mine of the company has grown steadily, although the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the technology and associated intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) as well as the first new drug program approval ($5 million), and even royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and many therapies, it’s this individual treatment in addition to a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple publications and multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this particular company. Judging with the multiples of a huge number of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *